FBT Fees and Costs — First Trust NYSE Arca Biotechnology Index Fund
Data updated: 2026-08-21
The net expense ratio is 0.55%: a 0.40% management fee plus 0.15% other expenses. There are no sales loads or redemption fees. In fiscal 2025 the fund paid $136K in broker commissions, 0.0120% of average net assets, and portfolio turnover was 37%.
FBT Fees and Expenses
Annual operating expenses and sales charges of FBT. Prospectus, as of December 31, 2025.
| Annual operating expenses | |
|---|---|
| Management fee | 0.40% |
| 12b-1 fee | 0.00% |
| Other expenses | 0.15% |
| Gross expense ratio | 0.55% |
| Fee waiver | — |
| Net expense ratio | 0.55% |
| Sales charges | |
|---|---|
| Max front load | 0.00% |
| Max deferred load | — |
| Redemption fee | — |
| Expense limitation in place (N-CEN) | Yes |
| Fees waived or reduced during the year | No |
| Waived fees subject to recoupment | No |
FBT Costs Over Time
On $10,000 invested in FBT, assuming 5% a year before costs, total costs come to $355 over 5 years, cutting the return by 0.59% a year. Illustration, not a forecast: it assumes today's net expense ratio throughout (a fee waiver may end).
| $10,000 invested | Sell after 1 year | Sell after 3 years | Sell after 5 years |
|---|---|---|---|
| Value before costs | $10,500 | $11,576 | $12,763 |
| Fund expenses (net expense ratio 0.55%) | $58 | $181 | $315 |
| Trading costs (broker commissions) | $1 | $4 | $7 |
| Lost growth on money paid in costs | $0 | $9 | $32 |
| Total costs | $59 | $194 | $355 |
| Value after costs | $10,441 | $11,382 | $12,408 |
| Impact on return, per year | 0.59% | 0.59% | 0.59% |
FBT Trading Costs
Brokerage costs reported on SEC Form N-CEN for the fiscal year ending December 31, 2025.
- Explicit cost rate (commissions ÷ average net assets): 0.0120%
- Total broker commissions: $136K
- Bought from dealers (principal trades, not a cost): $297.8M
- Portfolio turnover (prospectus): 37%
- Securities on loan, average value: $3.8M
- Net income from securities lending: $14K (0.001% of average net assets)
FBT Agency Brokers
Commissions paid.
| Broker | Amount | Share |
|---|---|---|
| GOLDMAN SACHS & CO. LLC | $48K | 35.61% |
| CANTOR FITZGERALD & CO. | $30K | 22.34% |
| BTIG, LLC | $28K | 20.65% |
| BOFA SECURITIES, INC. | $28K | 20.65% |
| CITADEL SECURITIES LLC | $1K | 0.75% |
FBT Dealer Counterparties
Securities bought directly from dealers (principal trades).
| Broker | Amount | Share |
|---|---|---|
| BOFA SECURITIES, INC. | $122.6M | 41.17% |
| JANE STREET CAPITAL, LLC | $74.2M | 24.90% |
| Intra-Cellular Therapies, Inc. | $52.1M | 17.50% |
| VIRTU AMERICAS LLC | $40.3M | 13.52% |
| GOLDMAN SACHS & CO. LLC | $8.7M | 2.91% |
For information only. Not investment advice: figures are as reported in SEC filings and may contain errors or be out of date. Past performance does not guarantee future results.